Create Free Account

By creating account you will get access to hot stocks & personalised emails

AbbVie Inc

Healthcare US ABBV

173.04USD
0.02(0.01%)

Last update at 2024-12-19T18:57:00Z

Day Range

170.34173.88
LowHigh

52 Week Range

145.95207.32
LowHigh

Fundamentals

  • Previous Close 173.02
  • Market Cap312023.91M
  • Volume2268009
  • P/E Ratio61.52
  • Dividend Yield3.72%
  • EBITDA25630.00M
  • Revenue TTM55533.00M
  • Revenue Per Share TTM31.40
  • Gross Profit TTM 41527.00M
  • Diluted EPS TTM2.87

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 13477.00M 12989.00M 3398.00M 8426.00M 5197.00M
Minority interest -9.00000M -7.00000M 6.00M 21.00M 21.00M
Net income 11836.00M 11542.00M 4616.00M 7882.00M 5687.00M
Selling general administrative 15260.00M 12349.00M 11299.00M 6942.00M 7399.00M
Selling and marketing expenses - - - - -
Gross profit 40640.00M 38751.00M 30417.00M 25827.00M 25035.00M
Reconciled depreciation 8467.00M 8521.00M 6471.00M 2017.00M 1765.00M
Ebit 18117.00M 17924.00M 476.00M 12983.00M 6383.00M
Ebitda 26584.00M 26445.00M 6947.00M 13795.00M 8148.00M
Depreciation and amortization 8467.00M 8521.00M 6471.00M 812.00M 1765.00M
Non operating income net other -2596.00000M -2551.00000M -5685.00000M -3048.00000M -42.00000M
Operating income 18117.00M 17924.00M 476.00M 12983.00M 6383.00M
Other operating expenses 39240.00M 37311.00M 33243.00M 19898.00M 25946.00M
Interest expense 2230.00M 2384.00M 2280.00M 1509.00M 1144.00M
Tax provision 1632.00M 1440.00M -1224.00000M 544.00M -490.00000M
Interest income 186.00M 39.00M 174.00M 275.00M 204.00M
Net interest income -2044.00000M -2384.00000M -2280.00000M -1509.00000M -1144.00000M
Extraordinary items - - - - -86.00000M
Non recurring 697.00M 962.00M 1198.00M 385.00M 424.00M
Other items - - - - -
Income tax expense 1632.00M 1440.00M -1224.00000M 544.00M -490.00000M
Total revenue 58054.00M 56197.00M 45804.00M 33266.00M 32753.00M
Total operating expenses 21826.00M 19865.00M 17856.00M 12459.00M 18228.00M
Cost of revenue 17414.00M 17446.00M 15387.00M 7439.00M 7718.00M
Total other income expense net -3293.00000M -3513.00000M 2922.00M -4557.00000M -466.00000M
Discontinued operations - - - - -
Net income from continuing ops 11845.00M 11549.00M 4622.00M 7882.00M 5687.00M
Net income applicable to common shares 11836.00M 11542.00M 4616.00M 7882.00M 5687.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 134711.00M 138805.00M 146529.00M 150565.00M 89115.00M
Intangible assets 55610.00M 67439.00M 75951.00M 82876.00M 18649.00M
Earning assets - - - - -
Other current assets 4932.00M 4401.00M 4993.00M 3562.00M 2354.00M
Total liab 124314.00M 121518.00M 131093.00M 137468.00M 97287.00M
Total stockholder equity 10360.00M 17254.00M 15408.00M 13076.00M -8172.00000M
Deferred long term liab - 2190.00M 3009.00M 3646.00M 1130.00M
Other current liab 26962.00M 22468.00M 19817.00M 17883.00M 10380.00M
Common stock 18.00M 18.00M 18.00M 18.00M 18.00M
Capital stock 18.00M 18.00M 18.00M 18.00M 18.00M
Retained earnings -1000.00000M 4784.00M 3127.00M 1055.00M 4717.00M
Other liab - 31716.00M 30982.00M 30401.00M 18476.00M
Good will 32293.00M 32156.00M 32379.00M 33124.00M 15604.00M
Other assets - 4834.00M 4081.00M 5144.00M 1913.00M
Cash 12814.00M 9201.00M 9746.00M 8449.00M 39924.00M
Cash and equivalents - - - - -
Total current liabilities 37841.00M 29538.00M 35194.00M 28661.00M 15585.00M
Current deferred revenue -3688.00000M - - - -
Net debt 46571.00M 54070.00M 66938.00M 77607.00M 26804.00M
Short term debt 7191.00M 4136.00M 12495.00M 8502.00M 3753.00M
Short long term debt 7191.00M 4136.00M 12495.00M 8502.00M 3753.00M
Short long term debt total 59385.00M 63271.00M 76684.00M 86056.00M 66728.00M
Other stockholder equity 13647.00M 14651.00M 15162.00M 15120.00M -9311.00000M
Property plant equipment - 4935.00M 5110.00M 5248.00M 2962.00M
Total current assets 33002.00M 28463.00M 27928.00M 24173.00M 49519.00M
Long term investments 304.00M 241.00M 277.00M 293.00M 93.00M
Net tangible assets - -82341.00000M -96202.00000M -102924.00000M -42425.00000M
Short term investments 2.00M 28.00M 84.00M 30.00M 0.00000M
Net receivables 11155.00M 11254.00M 9977.00M 8822.00M 5428.00M
Long term debt 52194.00M 59135.00M 64189.00M 77554.00M 62975.00M
Inventory 4099.00M 3579.00M 3128.00M 3310.00M 1813.00M
Accounts payable 3688.00M 2934.00M 2882.00M 2276.00M 1452.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 37.00M 33.00M 28.00M 21.00M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2305.00000M -2199.00000M -2899.00000M -3117.00000M -3596.00000M
Additional paid in capital 20180.00M - - - -
Common stock total equity - 18.00M 18.00M 18.00M 18.00M
Preferred stock total equity - - - - -
Retained earnings total equity - 4784.00M 3127.00M 1055.00M 4717.00M
Treasury stock -6533.00000M -4594.00000M -3143.00000M -2264.00000M -24504.00000M
Accumulated amortization - - - - -
Non currrent assets other 8513.00M 3381.00M 1875.00M 1205.00M 1158.00M
Deferred long term asset charges - - - - -
Non current assets total 101709.00M 110342.00M 118601.00M 126392.00M 39596.00M
Capital lease obligations - - - - -
Long term debt total - 59135.00M 64189.00M 77554.00M 62975.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -447.00000M -1398.00000M 114.00M 981.00M -368.00000M
Change to liabilities 2147.00M 338.00M 941.00M -1121.00000M 190.00M
Total cashflows from investing activities -623.00000M -2344.00000M -37557.00000M 596.00M -1006.00000M
Net borrowings -12433.00000M -8414.00000M -2703.00000M 25823.00M 3189.00M
Total cash from financing activities -24803.00000M -19039.00000M -11501.00000M 18708.00M -14396.00000M
Change to operating activities -264.00000M -197.00000M 134.00M 97.00M -499.00000M
Net income 11845.00M 11549.00M 4622.00M 7882.00M 5687.00M
Change in cash -545.00000M 1297.00M -31475.00000M 32635.00M -2014.00000M
Begin period cash flow 9746.00M 8449.00M 39924.00M 7289.00M 9303.00M
End period cash flow 9201.00M 9746.00M 8449.00M 39924.00M 7289.00M
Total cash from operating activities 24943.00M 22777.00M 17588.00M 13324.00M 13427.00M
Issuance of capital stock - - - - -
Depreciation 8467.00M 8521.00M 6471.00M 2017.00M 1765.00M
Other cashflows from investing activities 519.00M -159.00000M -36873.00000M 167.00M 167.00M
Dividends paid -10043.00000M -9261.00000M -7716.00000M -6366.00000M -5580.00000M
Change to inventory -686.00000M -142.00000M -40.00000M -231.00000M -226.00000M
Change to account receivables -1455.00000M -1321.00000M -929.00000M -74.00000M -591.00000M
Sale purchase of stock -1487.00000M -934.00000M -978.00000M -629.00000M -12014.00000M
Other cashflows from financing activities 1160.00M -674.00000M -333.00000M -552.00000M -104.00000M
Change to netincome 2646.00M 4029.00M 6389.00M 4754.00M 6677.00M
Capital expenditures 695.00M 787.00M 798.00M 552.00M 638.00M
Change receivables -1455.00000M -1321.00000M -929.00000M -74.00000M -591.00000M
Cash flows other operating 1979.00M -197.00000M 134.00M 97.00M -75.00000M
Exchange rate changes - -97.00000M -5.00000M 7.00M -39.00000M
Cash and cash equivalents changes -483.00000M 1297.00M -31475.00000M 32635.00M -2014.00000M
Change in working capital -258.00000M -1322.00000M 106.00M -1329.00000M -1126.00000M
Stock based compensation 671.00M 692.00M 753.00M 430.00M 421.00M
Other non cash items 6149.00M 4235.00M 7961.00M 3624.00M 6256.00M
Free cash flow 24248.00M 21990.00M 16790.00M 12772.00M 12789.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABBV
AbbVie Inc		 0.02 0.01% 173.04 61.52 14.86 5.62 51.62 6.76 20.58
LLY
Eli Lilly and Company		 -5.84 0.76% 758.87 103.14 46.73 16.88 48.24 17.43 69.11
JNJ
Johnson & Johnson		 -0.09 0.06% 144.66 29.17 14.33 3.74 5.18 3.80 15.22
MRK
Merck & Company Inc		 1.11 1.13% 99.45 59.83 12.33 4.50 6.47 4.94 23.79
AZN
AstraZeneca PLC ADR		 0.03 0.04% 64.67 38.69 16.31 4.67 5.46 5.20 17.74

Reports Covered

Stock Research & News

View All

Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc

1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Key Executives

Name Title Year Born
Mr. Richard A. Gonzalez Chairman & CEO 1954
Mr. Robert A. Michael Vice Chairman & Pres 1970
Ms. Laura J. Schumacher Vice Chairman of External Affairs & Chief Legal Officer 1963
Mr. Jeffrey Ryan Stewart Exec. VP & Chief Commercial Officer 1969
Mr. Scott T. Reents Exec. VP & CFO 1967
Dr. Azita Saleki-Gerhardt Ph.D. Exec. VP of Operations 1963
Dr. Thomas J. Hudson Sr. VP of R&D and Chief Scientific Officer 1962
Ms. Elizabeth Shea VP of Investor Relations NA
Mr. Perry C. Siatis Exec. VP, Gen. Counsel & Sec. NA
Mr. Timothy J. Richmond Exec. VP & Chief HR Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.